PGNY vs CLOV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 04, 2026

PGNY

48.6
AI Score
VS
CLOV Wins

CLOV

53.3
AI Score

Investment Advisor Scores

PGNY

49score
Recommendation
HOLD

CLOV

53score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric PGNY CLOV Winner
Revenue 1.49B 679.01M CLOV
Net Income 55.34M 52.28M CLOV
Net Margin 3.7% 7.7% PGNY
Operating Income 55.34M 75.38M PGNY
ROE 14.7% 11.5% CLOV
ROA 7.7% 7.3% CLOV
Total Assets 720.33M 715.84M CLOV
Current Ratio 1.50 2.14 PGNY
Free Cash Flow 131.55M 83.81M CLOV

Relative Price Performance (Last 90 Days)

PGNY 1M: -4.0% · 3M: -18.4% CLOV 1M: +1.9% · 3M: -13.4%

Current Technical Phase

PGNY

Markdown
Sell / avoid

Price below a falling SMA50 (slope -6.0%), weak momentum, RSI 40

RSI (14): 40.1 · Price: $25.23

CLOV

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -3.2%) with fading momentum, RSI 48

RSI (14): 47.6 · Price: $4.38

Fundamentals Snapshot

Metric PGNY CLOV
Market Cap — —
Forward P/E 10.9 29.2
Trailing P/E 27.3 —
Revenue (TTM) — —
Revenue Growth 0.1% 0.6%
Gross Margin 0.2% 0.2%
Operating Margin 0.1% 0.0%
EPS 0.91 -0.05
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CLOV is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.